Corcept Therapeutics Inc. (CORT) Stock Quote

Detailed Quote for Corcept Therapeutics Inc. (CORT)

After Hours: $ 2.90

0.14 (+5.07%)

Volume: 1.4 k

5:21 PM EST Feb 10, 2012

close 52 Week Information

52 Week High

June 3, 2011

Close: 5.07

52 Week Low

February 10, 2012

Close: 2.50

Today

Last Price
2.76

Change $
0.32

Change %
10.39%

Tick
N/A

Bid
N/A

Bid Size
0

Ask
N/A

Ask Size
0

Open
3.05

High
3.05

Low
2.50

Prev Close
3.08

Last Trade
2/10/12

Volume
1.54 m

52 Wk Hi
5.07

52 Wk Low
2.50

Market Cap
232.48 m

Ex-Div Date
N/A

Div Rate
N/A

Yield
N/A

Shares
84,231,243

EPS (TTM)
-0.38

PE Ratio
N/A

close Exchange Information Listed On Nasdaq Small Caps (NSC) Exchange
NSC

News and Media for Corcept Therapeutics Inc. (CORT)

Sector News | Topic News

News for CORT

Thu, Dec 15, 2011

9:01 AM

FDA Will Not Require a Risk Evaluation and Mitigation Strategy in Connection With Corcept's Proposed Distribution of Korlym(TM) for Cushing's Syndrome - Marketwire

Mon, Nov 07, 2011

9:00 AM

Corcept Therapeutics Announces Third Quarter Results and Corporate and Development Update - Marketwire

Mon, Aug 22, 2011

9:00 AM

Gary C. Robb Joins Corcept as Chief Financial Officer - Marketwire

9:00 AM

No FDA Advisory Committee Meeting Planned in Connection With New Drug Application for CORLUX for Cushing's Syndrome - Marketwire

Mon, Aug 08, 2011

8:00 AM

Corcept Therapeutics Announces Second Quarter Results and Corporate and Development Update - Marketwire

Thu, Jun 30, 2011

8:00 AM

FDA Accepts Submission of New Drug Application for CORLUX for Cushing's Syndrome - Marketwire

Sat, Jun 04, 2011

12:45 PM

Corcept Therapeutics Announces Detailed Findings From Phase 3 Study Which Show CORLUX Significantly Improves Clinical and Metabolic Manifestations of Cushing's Syndrome - Marketwire

Wed, Jun 01, 2011

8:00 AM

Corcept Therapeutics Announces Conference Call to Discuss Detailed Findings From Corlux Phase 3 Trial in Cushing's Syndrome at the Endocrine Society's Annual Meeting - Marketwire

Thu, May 19, 2011

8:00 AM

Corcept Therapeutics to Present Detailed Findings From CORLUX Phase 3 Trial in Cushing's Syndrome at the Endocrine Society's Annual Meeting, June 4-7 - Marketwire

Wed, May 04, 2011

8:00 AM

Corcept Therapeutics Announces First Quarter Results and Corporate and Development Update - Marketwire

Fri, Apr 15, 2011

4:05 PM

Corcept Therapeutics Announces NDA Submitted to the FDA for the Use of CORLUX in Cushing's Syndrome - Marketwire

Thu, Mar 31, 2011

4:28 PM

Corcept Therapeutics Announces NDA Submission to Be Completed the Week of April 11, 2011 - Marketwire

Wed, Mar 09, 2011

8:00 AM

Corcept Therapeutics Announces Fourth Quarter Results and Corporate and Development Update - Marketwire

Fri, May 08, 2009

5:28 PM

AllPennyStocks.com Announces May 11th to May 15th U.S. Penny Stocks 2 Watch (CORT, HSPO.OB) - Accesswire

More News for CORT >>

Tags for Corcept Therapeutics Inc.